305 related articles for article (PubMed ID: 26802734)
1. AISF-SIMTI Position Paper: The appropriate use of albumin in patients with liver cirrhosis.
;
Dig Liver Dis; 2016 Jan; 48(1):4-15. PubMed ID: 26802734
[TBL] [Abstract][Full Text] [Related]
2. AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis.
Caraceni P; Angeli P; Prati D; Bernardi M; ; Liumbruno GM; Bennardello F; Piccoli P; Velati C;
Blood Transfus; 2016 Jan; 14(1):8-22. PubMed ID: 26820615
[TBL] [Abstract][Full Text] [Related]
3. Albumin: Indications in chronic liver disease.
Tufoni M; Zaccherini G; Caraceni P; Bernardi M
United European Gastroenterol J; 2020 Jun; 8(5):528-535. PubMed ID: 32213034
[TBL] [Abstract][Full Text] [Related]
4. Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients: a randomized pilot study.
Hamdy H; ElBaz AA; Hassan A; Hassanin O
J Clin Gastroenterol; 2014 Feb; 48(2):184-8. PubMed ID: 23842215
[TBL] [Abstract][Full Text] [Related]
5. Clinical indications for the albumin use: still a controversial issue.
Caraceni P; Domenicali M; Tovoli A; Napoli L; Ricci CS; Tufoni M; Bernardi M
Eur J Intern Med; 2013 Dec; 24(8):721-8. PubMed ID: 23790570
[TBL] [Abstract][Full Text] [Related]
6. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.
Appenrodt B; Wolf A; Grünhage F; Trebicka J; Schepke M; Rabe C; Lammert F; Sauerbruch T; Heller J
Liver Int; 2008 Aug; 28(7):1019-25. PubMed ID: 18410283
[TBL] [Abstract][Full Text] [Related]
7. Management of ascites and hepatorenal syndrome.
Piano S; Tonon M; Angeli P
Hepatol Int; 2018 Feb; 12(Suppl 1):122-134. PubMed ID: 28836115
[TBL] [Abstract][Full Text] [Related]
8. Albumin administration in patients with cirrhosis: Current role and novel perspectives.
de Mattos ÂZ; Simonetto DA; Terra C; Farias AQ; Bittencourt PL; Pase THS; Toazza MR; de Mattos AA;
World J Gastroenterol; 2022 Sep; 28(33):4773-4786. PubMed ID: 36156923
[TBL] [Abstract][Full Text] [Related]
9. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem.
Arroyo V; Jiménez W
J Hepatol; 2000; 32(1 Suppl):157-70. PubMed ID: 10728802
[TBL] [Abstract][Full Text] [Related]
10. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites.
Di Pascoli M; Fasolato S; Piano S; Bolognesi M; Angeli P
Liver Int; 2019 Jan; 39(1):98-105. PubMed ID: 30230204
[TBL] [Abstract][Full Text] [Related]
11. [The use of albumin infusion in decompensated liver cirrhosis].
Schmidt LE; Ring-Larsen H
Ugeskr Laeger; 2002 Feb; 164(9):1196-202. PubMed ID: 11899505
[TBL] [Abstract][Full Text] [Related]
12. Drug insight: the role of albumin in the management of chronic liver disease.
Wong F
Nat Clin Pract Gastroenterol Hepatol; 2007 Jan; 4(1):43-51. PubMed ID: 17203088
[TBL] [Abstract][Full Text] [Related]
13. [When should we give albumin in patients with cirrhosis?].
Bochatay L; Elkrief L; Spahr L
Rev Med Suisse; 2015 Sep; 11(484):1596, 1598-601. PubMed ID: 26502620
[TBL] [Abstract][Full Text] [Related]
14. [Albumin infusion for paracentesis in patients with cirrhosis: dogma or evidence?].
Manzocchi S; Nendaz M; Spahr L
Rev Med Suisse; 2012 Oct; 8(358):1956, 1958-60. PubMed ID: 23198648
[TBL] [Abstract][Full Text] [Related]
15. Role of albumin in the treatment of decompensated liver cirrhosis.
Trebicka J
Curr Opin Gastroenterol; 2022 May; 38(3):200-205. PubMed ID: 35275900
[TBL] [Abstract][Full Text] [Related]
16. The clinical management of abdominal ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: a review of current guidelines and recommendations.
Pericleous M; Sarnowski A; Moore A; Fijten R; Zaman M
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):e10-8. PubMed ID: 26671516
[TBL] [Abstract][Full Text] [Related]
17. Hyponatremia in cirrhosis.
Sigal SH
J Hosp Med; 2012 Apr; 7 Suppl 4():S14-7. PubMed ID: 22489081
[TBL] [Abstract][Full Text] [Related]
18. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.
Ginès P; Uriz J; Calahorra B; Garcia-Tsao G; Kamath PS; Del Arbol LR; Planas R; Bosch J; Arroyo V; Rodés J
Gastroenterology; 2002 Dec; 123(6):1839-47. PubMed ID: 12454841
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of ascites, hyponatremia and hepatorenal syndrome in liver cirrhosis].
Ackermann D
Ther Umsch; 2009 Nov; 66(11):747-51. PubMed ID: 19885792
[TBL] [Abstract][Full Text] [Related]
20. How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure.
Mirici-Cappa F; Caraceni P; Domenicali M; Gelonesi E; Benazzi B; Zaccherini G; Trevisani F; Puggioli C; Bernardi M
World J Gastroenterol; 2011 Aug; 17(30):3479-86. PubMed ID: 21941414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
